Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Alexopoulos

Showing results (111-120 of 139) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
British Journal of Cancer|October 12, 2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, M Paesmans, et al.
Current Vascular Pharmacology|November 1, 2021
Epicardial Adipocyte-derived TNF-α Modulates Local Inflammation in Patients with Advanced Coronary Artery DiseaseNikoleta Karampetsou, Aspasia Tzani, Ilias P Doulamis, et al.
Journal of Cellular and Molecular Medicine|October 1, 2019
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cellsAikaterini Skorda, Aimilia D Sklirou, Theodore Sakellaropoulos, et al.
Toxicology and Applied Pharmacology|April 14, 2009
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicityBenjamin D Cosgrove, Bracken M King, Maya A Hasan, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2007
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
Kidney International|May 29, 2021
Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosisInsa M Schmidt, Mia R Colona, Bryan R Kestenbaum, et al.
Scientific Reports|March 24, 2021
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assaysChristos Fotis, Nikolaos Meimetis, Nikos Tsolakos, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 2, 2011
Participants in the workshopG Alexopoulos, E D Caine, I Katz, et al.
Pageof 14

Showing results (111-120 of 139) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
British Journal of Cancer|October 12, 2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, M Paesmans, et al.
Current Vascular Pharmacology|November 1, 2021
Epicardial Adipocyte-derived TNF-α Modulates Local Inflammation in Patients with Advanced Coronary Artery DiseaseNikoleta Karampetsou, Aspasia Tzani, Ilias P Doulamis, et al.
Journal of Cellular and Molecular Medicine|October 1, 2019
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cellsAikaterini Skorda, Aimilia D Sklirou, Theodore Sakellaropoulos, et al.
Toxicology and Applied Pharmacology|April 14, 2009
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicityBenjamin D Cosgrove, Bracken M King, Maya A Hasan, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2007
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
Kidney International|May 29, 2021
Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosisInsa M Schmidt, Mia R Colona, Bryan R Kestenbaum, et al.
Scientific Reports|March 24, 2021
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assaysChristos Fotis, Nikolaos Meimetis, Nikos Tsolakos, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 2, 2011
Participants in the workshopG Alexopoulos, E D Caine, I Katz, et al.
Pageof 14